Juno Therapeutics, Inc.
🏢 View company profile →65Patents
65Active
65Granted
55Portfolio score
Filing activity: Feb 25, 2013 → Dec 16, 2024
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11400115B2 | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy | Emerging Cross-Sectional Technologies | 11 | Active |
| US10228312B2 | Chromatographic isolation of cells and other complex biological materials | Physics | 11 | Active |
| US11413310B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | Human Necessities | 10 | Active |
| US10533055B2 | Antibodies and chimeric antigen receptors specific for CD19 | Chemistry; Metallurgy | 9 | Active |
| US11020429B2 | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy | Chemistry; Metallurgy | 6 | Active |
| US11466253B2 | Methods for culturing cells and kits and apparatus for same | Chemistry; Metallurgy | 6 | Active |
| US10428351B2 | Methods for transduction and cell processing | Chemistry; Metallurgy | 6 | Active |
| US11066475B2 | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides | Chemistry; Metallurgy | 5 | Active |
| US11248238B2 | Methods, kits, agents and apparatuses for transduction | Chemistry; Metallurgy | 5 | Active |
| US11274278B2 | Methods, kits and apparatus for expanding a population of cells | Chemistry; Metallurgy | 5 | Active |
| US10363269B2 | Modified hepatitis post-transcriptional regulatory elements | Chemistry; Metallurgy | 5 | Active |
| US10738278B2 | Engineered cells for adoptive cell therapy | Chemistry; Metallurgy | 4 | Active |
| US10889652B2 | Antibodies and chimeric antigen receptors specific for ROR1 | Chemistry; Metallurgy | 3 | Active |
| US10507219B2 | Methods and compositions for dosing in adoptive cell therapy | Chemistry; Metallurgy | 3 | Active |
| US11866465B2 | Oligomeric particle reagents and methods of use thereof | Chemistry; Metallurgy | 3 | Active |
| US11944647B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | Human Necessities | 2 | Active |
| US11815514B2 | Methods and compositions related to toxicity associated with cell therapy | Chemistry; Metallurgy | 2 | Active |
| US11623961B2 | Antibodies and chimeric antigen receptors specific for B-cell maturation antigen | Chemistry; Metallurgy | 2 | Active |
| US11851678B2 | Methods for producing genetically engineered cell compositions and related compositions | Physics | 2 | Active |
| US10786533B2 | Engineered cells for adoptive cell therapy | Chemistry; Metallurgy | 2 | Active |
| US11072660B2 | HPV-specific binding molecules | Chemistry; Metallurgy | 2 | Active |
| US11913024B2 | Methods for culturing cells and kits and apparatus for same | Chemistry; Metallurgy | 2 | Active |
| US11564946B2 | Methods associated with tumor burden for assessing response to a cell therapy | Physics | 2 | Active |
| US11919970B2 | Antibodies and chimeric antigen receptors specific for ROR1 | Chemistry; Metallurgy | 1 | Active |
| US11421287B2 | Methods for assessing the presence or absence of replication competent virus | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.